Figure 5
Repeated tumor challenges foster non-HA immune response. Six-week-old BALB/c mice were injected i.v. with 125 μg PC61 at day −1 to deplete Tregs (n=5, gray line) or PBS (n=5, black line) and subsequently injected s.c. with 5 × 105 AB1-HA tumor cells at day 0. Mice that had rejected the first tumor (4/5) were rechallenged s.c. 1.5 months later with 5 × 105 AB1-HA, as well as 4 naive age-matched BALB/c mice (left insert). Mice that rejected the second tumor (4/4) were again rechallenged 1.5 months later with 5 × 105 AB1-HA as well as 4 naive age-matched BALB/c mice (middle insert). Mice that rejected the third AB1-HA tumor (4/4) were rechallenged 1 month later with 1 × 105 4T1 as well as 4 naive age-matched BALB/c mice (right insert). Graphs show the tumor volume growth (mm3).
